Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2016 · 10-Q
Revenue$3.68M$3.68M+8.5% vs Q1 2015 Net Income-$2.34M-$2.34MN/M vs Q1 2015 EPS Diluted-$0.77-$0.77N/M vs Q1 2015 Gross Profit$1,873,000−1.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$2,585,000N/M Free Cash Flowderived-$2,733,000N/M Margins · derivedGross margin50.9%−5.3 pt vs Q1 2015
Operating margin-62.8%−18.2 pt vs Q1 2015
Net margin-63.6%−61.5 pt vs Q1 2015
ended Jun 30, 2015 · filed Aug 7, 2015 · 38 d after period end